Skip to main content

Raynaud's Disease

4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
2 programs
2
PletalPhase 41 trial
PletalPhase 41 trial
Active Trials
NCT00048763Completed75Est. Jun 2003
NCT00048776Completed75Est. Jun 2003
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-00489791Phase 21 trial
Active Trials
NCT01090492Completed243Est. May 2011
Response Pharmaceuticals
Response PharmaceuticalsVA - Falls Church
1 program
1
SLx-2101Phase 21 trial
Active Trials
NCT00528242Completed17Est. Mar 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OtsukaPletal
OtsukaPletal
PfizerPF-00489791
Response PharmaceuticalsSLx-2101

Clinical Trials (4)

Total enrollment: 410 patients across 4 trials

NCT00048763OtsukaPletal

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Start: Oct 2001Est. completion: Jun 200375 patients
Phase 4Completed
NCT00048776OtsukaPletal

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Start: Oct 2001Est. completion: Jun 200375 patients
Phase 4Completed
NCT01090492PfizerPF-00489791

PF-00489791 For The Treatment Of Raynaud's

Start: Aug 2010Est. completion: May 2011243 patients
Phase 2Completed
NCT00528242Response PharmaceuticalsSLx-2101

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Start: Jun 2007Est. completion: Mar 200817 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.